Shanghai Fosun Pharmaceutical’s SBK010 Stroke Treatment Accepted for NMPA Review
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
3D Medicines’ H1’24 Financials Reflect Increased Comprehensive Loss Amid Revenue Decline
3D Medicines (HKG: 1244), a China-based oncology specialist, has released its financial report for the...
China Sets New Management Measures for Investigator-Initiated Trials in Medical Institutions
The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...
China Unveils Medical Insurance Eligibility Management System for Designated Healthcare Personnel
The National Healthcare Security Administration (NHSA), National Health Commission, and National Medical Products Administration (NMPA)...
OrbusNeich Medical Group Partners with Abbott’s CSI as Sole Distributor
Shenzhen-based vascular intervention specialist OrbusNeich Medical Group Ltd (HKG: 6929) has announced a significant distribution...
Jacobio Pharma Receives NMPA Approval for Pan-KRAS Inhibitor JAB-23E73 Clinical Trial
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has received approval from the...
AstraZeneca’s Tagrisso Secures FDA Approval for Unresectable Stage III EGFRm NSCLC
AstraZeneca (NASDAQ: AZN, LON: AZN), a UK-based pharmaceutical giant, has announced that it has received...
Jacobio Pharma Receives RMB 172 Million Milestone Payment from Allist Pharmaceuticals
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the receipt of...
Apeloa Pharmaceutical Partners with Biocre Tech to Boost Pharmaceutical Innovation
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a pharmaceutical company based in China, has entered into...
FDA Approves Cobenfy as Novel Schizophrenia Treatment with First-in-Decades Mechanism
The U.S. Food and Drug Administration (FDA) has granted official approval to Cobenfy (KarXT, xanomeline...
Hunan Province Includes Fertility Treatments in Medical Insurance Coverage from October 2024
The Hunan Healthcare Security Administration has issued a notification to include specific assisted reproductive medical...
Shanghai Junshi Biosciences Inks Licensing Deal for IAMA-001 Nasal Spray with Nanjing JSIAMA
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China,...
China’s Pharmaceutical Industry Sees Mixed Results in H1 2024, CAPEM Data Reveals
The China Association of Pharmaceutical Enterprises Management (CAPEM) has released a comprehensive set of data...
Shanghai Medical Procurement Platform Sets Price Cap for Non-Locally Supplied Drugs
Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) has issued a notification concerning the online procurement prices...
Pfizer Partners with Shanghai Pharmaceutical for Long-Term Vaccine Collaboration in China
Pfizer Inc. (NSE: PFIZER, NYSE: PFE, ETR: PFE), a leading pharmaceutical company in the U.S.,...
FDA Panel Weighs in on Narrowing Use of PD-1 Inhibitors in Stomach and Esophageal Cancers
The U.S. FDA’s Oncologic Drugs Advisory Committee (ODAC) convened on September 26 to scrutinize the...
2seventy bio and BMS Discontinue Phase III Trial for Multiple Myeloma Therapy Abecma
2seventy bio Inc. (NASDAQ: TSVT), a U.S.-based biotechnology company partnered with Bristol-Myers Squibb (BMS, NYSE:...
Zelgen Biopharmaceuticals Receives NMPA Approval for ZG005 Clinical Trial in Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
Johnson & Johnson Reportedly Winding Down Cardiovascular and Metabolic Pharma Unit
Johnson & Johnson (J&J; NYSE: JNJ), a healthcare giant in the U.S., is reportedly winding...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for Generic Vizamyl Clinical Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...